<p>Werewolf Therapeutics, Inc.（纳斯达克代码：HOWL - 获取免费报告）董事 Luke Evnin 于 12 月 16 日（星期二）出售了 14,548 股 Werewolf Therapeutics 股票。该股票以平均价格 1.05 美元出售，总交易额为 15,275.40 美元。出售完成后，该董事直接持有公司 2,851,940 股股票，价值 2,994,537 美元。此交易代表其持股减少了 0.51%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此超链接获取。</p>
<p>Luke Evnin 最近还进行了以下交易：</p>
<ul>
<li>12 月 17 日（星期三），Luke Evnin 出售了 9,983 股 Werewolf Therapeutics 股票。该股票以平均价格 1.14 美元出售，总价值为 11,380.62 美元。</li>
<li>12 月 15 日（星期一），Luke Evnin 出售了 23,640 股 Werewolf Therapeutics 股票。该股票以平均价格 1.07 美元出售，总交易额为 25,294.80 美元。</li>
<li>12 月 12 日（星期五），Luke Evnin 出售了 17,858 股 Werewolf Therapeutics 股票。该股票以平均价格 1.08 美元出售，总交易额为 19,286.64 美元。</li>
<li>12 月 11 日（星期四），Luke Evnin 出售了 28,009 股 Werewolf Therapeutics 股票。该股票以平均价格 1.07 美元出售，总价值为 29,969.63 美元。</li>
<li>12 月 10 日（星期三），Luke Evnin 出售了 37,104 股 Werewolf Therapeutics 股票。该股票以平均价格 1.06 美元出售，总价值为 39,330.24 美元。</li>
<li>12 月 9 日（星期二），Luke Evnin 出售了 44,570 股 Werewolf Therapeutics 股票。该股票以平均价格 1.01 美元出售，总交易额为 45,015.70 美元。</li>
<li>12 月 8 日（星期一），Luke Evnin 出售了 34,041 股 Werewolf Therapeutics 股票。该股票以平均价格 0.99 美元出售，总交易额为 33,700.59 美元。</li>
<li>12 月 5 日（星期五），Luke Evnin 出售了 16,568 股 Werewolf Therapeutics 股票。该股票以平均价格 0.97 美元出售，总价值为 16,070.96 美元。</li>
<li>12 月 4 日（星期四），Luke Evnin 出售了 53,416 股 Werewolf Therapeutics 股票。该股票以平均价格 0.97 美元出售，总价值为 51,813.52 美元。</li>
<li>12 月 3 日（星期三），Luke Evnin 出售了 36,726 股 Werewolf Therapeutics 股票。该股票以平均价格 0.87 美元出售，总交易额为 31,951.62 美元。</li>
</ul>
<p>获取 <strong>Werewolf Therapeutics</strong> 的提醒：</p>
<h2>Werewolf Therapeutics 价格表现</h2>
<p>在周三的午盘交易中，纳斯达克：HOWL 下跌 0.01 美元，报 1.07 美元。该公司的交易量为 468,373 股，而其平均交易量为 445,417 股。该公司的速动比率为 3.87，流动比率为 3.87，债务与股本比率为 0.73。该公司的市值为 5194 万美元，市盈率为-0.66，贝塔值为 0.74。该股票的 50 日移动平均价格为 1.24 美元，200 日移动平均价格为 1.32 美元。Werewolf Therapeutics, Inc.的 52 周低点为 0.60 美元，52 周高点为 2.38 美元。</p>
<p>Werewolf Therapeutics（纳斯达克：HOWL - 获取免费报告）最近于 11 月 4 日（星期二）公布了季度财报。该公司报告每股收益为（0.36 美元），超出分析师一致预期的（0.39 美元）0.03 美元。整体来看，研究分析师预计 Werewolf Therapeutics, Inc.在本年度将发布-1.56 美元的每股收益。</p>
<h2>华尔街分析师观点</h2>
<p>HOWL 已成为多份分析师报告的主题。Zacks Research 在 11 月 21 日（星期五）的报告中将 Werewolf Therapeutics 的评级从 “强力买入” 下调至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Werewolf Therapeutics 股票的 “卖出（d-）” 评级。美国银行在 11 月 18 日（星期二）的研究报告中将 Werewolf Therapeutics 的目标价格从 8.00 美元下调至 7.00 美元，并对该公司给予 “买入” 评级。JMP Securities 在 8 月 21 日（星期四）的研究报告中将 Werewolf Therapeutics 的目标价格从 4.00 美元下调至 3.00 美元，并对该公司给予 “市场表现优于大盘” 评级。最后，花旗集团在 11 月 12 日（星期三）的研究报告中重新发布了对 Werewolf Therapeutics 股票的 “市场表现优于大盘” 评级。五家股票研究分析师对该股票给予了买入评级，一家给予了持有评级，一家给予了卖出评级。根据 MarketBeat，Werewolf Therapeutics 目前的共识评级为 “适度买入”，平均目标价格为 7.75 美元。</p>
<p><strong>阅读我们关于 HOWL 的最新股票报告</strong></p>
<h2>机构投资者对 Werewolf Therapeutics 的看法</h2>
<p>一些大型投资者最近增加或减少了对 HOWL 的持股。查尔斯·施瓦布投资管理公司在第一季度将其在 Werewolf Therapeutics 的持股增加了 33.2%。查尔斯·施瓦布投资管理公司目前拥有 95,712 股该公司的股票，价值 93,000 美元，此前在该期间内又购买了 23,852 股。Nuveen LLC 在第一季度购买了 Werewolf Therapeutics 的新股份，价值约 71,000 美元。MPM 资产管理公司在第一季度将其在 Werewolf Therapeutics 的持股增加了 0.6%。MPM 资产管理公司目前拥有 4,309,860 股该公司的股票，价值 4,189,000 美元，此前在上一季度又购买了 25,688 股。MPM Bioimpact LLC 在第一季度将其在 Werewolf Therapeutics 的持股增加了 0.9%。MPM Bioimpact LLC 目前拥有 2,408,810 股该公司的股票，价值 2,341,000 美元，此前在上一季度又购买了 20,799 股。最后，AQR 资本管理公司在第一季度购买了 Werewolf Therapeutics 的新股份，价值约 79,000 美元。机构投资者持有该公司 64.84% 的股票。</p>
<h2>Werewolf Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Werewolf Therapeutics, Inc.是一家生物制药公司，开发旨在刺激身体免疫系统以治疗癌症的疗法。该公司通过其专有的 PREDATOR 平台，设计条件激活分子，以刺激适应性和先天免疫，解决传统促炎免疫疗法的局限性。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Werewolf Therapeutics</li>
<li>市值计算器：如何计算市值</li>
<li>在股价上涨 35% 后，分析师看好铜业巨头 Freeport 的进一步上涨</li>
<li>如何利用高贝塔股票最大化投资收益</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的主要催化剂</li>
<li>如何投资生物科技股票</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9XTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9XTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Werewolf Therapeutics 吗？</h2>
<p>在考虑 Werewolf Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Werewolf Therapeutics 并不在名单上。</p>
<p>虽然 Werewolf Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

HOWL

<p>Werewolf Therapeutics 的董事 Luke Evnin 以每股 1.05 美元的价格出售了 14,548 股，总计 15,275.40 美元。出售后，他持有 2,851,940 股，减少了 0.51%。该交易已向美国证券交易委员会（SEC）备案。Evnin 在 12 月进行了多次出售，价格和数量各不相同。Werewolf 的股票表现显示 52 周的价格区间为 0.60 美元至 2.38 美元，近期分析师评级不一，包括下调评级和目标价格调整</p>

<p>Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $1.05, for a total transaction of $15,275.40. Following the completion of the sale, the director directly owned 2,851,940 shares in the company, valued at $2,994,537. This trade represents a 0.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.</p>
<div class="lb-trans"><p>Werewolf Therapeutics, Inc.（纳斯达克代码：HOWL - 获取免费报告）董事 Luke Evnin 于 12 月 16 日（星期二）出售了 14,548 股 Werewolf Therapeutics 股票。该股票以平均价格 1.05 美元出售，总交易额为 15,275.40 美元。出售完成后，该董事直接持有公司 2,851,940 股股票，价值 2,994,537 美元。此交易代表其持股减少了 0.51%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此超链接获取。</p>
</div><p>Luke Evnin also recently made the following trade(s):</p>
<div class="lb-trans"><p>Luke Evnin 最近还进行了以下交易：</p>
</div><ul>
<li>On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $11,380.62.</li>
<li>On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total transaction of $25,294.80.</li>
<li>On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.08, for a total transaction of $19,286.64.</li>
<li>On Thursday, December 11th, Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.07, for a total value of $29,969.63.</li>
<li>On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total value of $39,330.24.</li>
<li>On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.01, for a total transaction of $45,015.70.</li>
<li>On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $33,700.59.</li>
<li>On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total value of $16,070.96.</li>
<li>On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.</li>
<li>On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total transaction of $31,951.62.</li>
</ul>
<div class="lb-trans"><ul>
<li>12 月 17 日（星期三），Luke Evnin 出售了 9,983 股 Werewolf Therapeutics 股票。该股票以平均价格 1.14 美元出售，总价值为 11,380.62 美元。</li>
<li>12 月 15 日（星期一），Luke Evnin 出售了 23,640 股 Werewolf Therapeutics 股票。该股票以平均价格 1.07 美元出售，总交易额为 25,294.80 美元。</li>
<li>12 月 12 日（星期五），Luke Evnin 出售了 17,858 股 Werewolf Therapeutics 股票。该股票以平均价格 1.08 美元出售，总交易额为 19,286.64 美元。</li>
<li>12 月 11 日（星期四），Luke Evnin 出售了 28,009 股 Werewolf Therapeutics 股票。该股票以平均价格 1.07 美元出售，总价值为 29,969.63 美元。</li>
<li>12 月 10 日（星期三），Luke Evnin 出售了 37,104 股 Werewolf Therapeutics 股票。该股票以平均价格 1.06 美元出售，总价值为 39,330.24 美元。</li>
<li>12 月 9 日（星期二），Luke Evnin 出售了 44,570 股 Werewolf Therapeutics 股票。该股票以平均价格 1.01 美元出售，总交易额为 45,015.70 美元。</li>
<li>12 月 8 日（星期一），Luke Evnin 出售了 34,041 股 Werewolf Therapeutics 股票。该股票以平均价格 0.99 美元出售，总交易额为 33,700.59 美元。</li>
<li>12 月 5 日（星期五），Luke Evnin 出售了 16,568 股 Werewolf Therapeutics 股票。该股票以平均价格 0.97 美元出售，总价值为 16,070.96 美元。</li>
<li>12 月 4 日（星期四），Luke Evnin 出售了 53,416 股 Werewolf Therapeutics 股票。该股票以平均价格 0.97 美元出售，总价值为 51,813.52 美元。</li>
<li>12 月 3 日（星期三），Luke Evnin 出售了 36,726 股 Werewolf Therapeutics 股票。该股票以平均价格 0.87 美元出售，总交易额为 31,951.62 美元。</li>
</ul>
</div><p>Get <strong>Werewolf Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Werewolf Therapeutics</strong> 的提醒：</p>
</div><h2>Werewolf Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Werewolf Therapeutics 价格表现</h2>
</div><p>NASDAQ:HOWL traded down $0.01 during midday trading on Wednesday, hitting $1.07. The company had a trading volume of 468,373 shares, compared to its average volume of 445,417. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $51.94 million, a PE ratio of -0.66 and a beta of 0.74. The stock's fifty day moving average price is $1.24 and its 200-day moving average price is $1.32. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38.</p>
<div class="lb-trans"><p>在周三的午盘交易中，纳斯达克：HOWL 下跌 0.01 美元，报 1.07 美元。该公司的交易量为 468,373 股，而其平均交易量为 445,417 股。该公司的速动比率为 3.87，流动比率为 3.87，债务与股本比率为 0.73。该公司的市值为 5194 万美元，市盈率为-0.66，贝塔值为 0.74。该股票的 50 日移动平均价格为 1.24 美元，200 日移动平均价格为 1.32 美元。Werewolf Therapeutics, Inc.的 52 周低点为 0.60 美元，52 周高点为 2.38 美元。</p>
</div><p>Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03. As a group, research analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.</p>
<div class="lb-trans"><p>Werewolf Therapeutics（纳斯达克：HOWL - 获取免费报告）最近于 11 月 4 日（星期二）公布了季度财报。该公司报告每股收益为（0.36 美元），超出分析师一致预期的（0.39 美元）0.03 美元。整体来看，研究分析师预计 Werewolf Therapeutics, Inc.在本年度将发布-1.56 美元的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>HOWL has been the topic of several analyst reports. Zacks Research downgraded Werewolf Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, November 21st. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Bank of America dropped their target price on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, November 18th. JMP Securities lowered their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a &#34;market outperform&#34; rating for the company in a research note on Thursday, August 21st. Finally, Citigroup reissued a &#34;market outperform&#34; rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Werewolf Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $7.75.</p>
<div class="lb-trans"><p>HOWL 已成为多份分析师报告的主题。Zacks Research 在 11 月 21 日（星期五）的报告中将 Werewolf Therapeutics 的评级从 “强力买入” 下调至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了对 Werewolf Therapeutics 股票的 “卖出（d-）” 评级。美国银行在 11 月 18 日（星期二）的研究报告中将 Werewolf Therapeutics 的目标价格从 8.00 美元下调至 7.00 美元，并对该公司给予 “买入” 评级。JMP Securities 在 8 月 21 日（星期四）的研究报告中将 Werewolf Therapeutics 的目标价格从 4.00 美元下调至 3.00 美元，并对该公司给予 “市场表现优于大盘” 评级。最后，花旗集团在 11 月 12 日（星期三）的研究报告中重新发布了对 Werewolf Therapeutics 股票的 “市场表现优于大盘” 评级。五家股票研究分析师对该股票给予了买入评级，一家给予了持有评级，一家给予了卖出评级。根据 MarketBeat，Werewolf Therapeutics 目前的共识评级为 “适度买入”，平均目标价格为 7.75 美元。</p>
</div><p><strong>Read Our Latest Stock Report on HOWL</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 HOWL 的最新股票报告</strong></p>
</div><h2>Institutional Investors Weigh In On Werewolf Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Werewolf Therapeutics 的看法</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in HOWL. Charles Schwab Investment Management Inc. grew its holdings in shares of Werewolf Therapeutics by 33.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company's stock worth $93,000 after acquiring an additional 23,852 shares during the period. Nuveen LLC purchased a new stake in Werewolf Therapeutics in the 1st quarter worth approximately $71,000. MPM Asset Management LLC increased its stake in shares of Werewolf Therapeutics by 0.6% in the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company's stock worth $4,189,000 after purchasing an additional 25,688 shares in the last quarter. MPM Bioimpact LLC increased its stake in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company's stock worth $2,341,000 after buying an additional 20,799 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the 1st quarter valued at approximately $79,000. Institutional investors own 64.84% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了对 HOWL 的持股。查尔斯·施瓦布投资管理公司在第一季度将其在 Werewolf Therapeutics 的持股增加了 33.2%。查尔斯·施瓦布投资管理公司目前拥有 95,712 股该公司的股票，价值 93,000 美元，此前在该期间内又购买了 23,852 股。Nuveen LLC 在第一季度购买了 Werewolf Therapeutics 的新股份，价值约 71,000 美元。MPM 资产管理公司在第一季度将其在 Werewolf Therapeutics 的持股增加了 0.6%。MPM 资产管理公司目前拥有 4,309,860 股该公司的股票，价值 4,189,000 美元，此前在上一季度又购买了 25,688 股。MPM Bioimpact LLC 在第一季度将其在 Werewolf Therapeutics 的持股增加了 0.9%。MPM Bioimpact LLC 目前拥有 2,408,810 股该公司的股票，价值 2,341,000 美元，此前在上一季度又购买了 20,799 股。最后，AQR 资本管理公司在第一季度购买了 Werewolf Therapeutics 的新股份，价值约 79,000 美元。机构投资者持有该公司 64.84% 的股票。</p>
</div><h2>Werewolf Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Werewolf Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.</p>
<div class="lb-trans"><p>Werewolf Therapeutics, Inc.是一家生物制药公司，开发旨在刺激身体免疫系统以治疗癌症的疗法。该公司通过其专有的 PREDATOR 平台，设计条件激活分子，以刺激适应性和先天免疫，解决传统促炎免疫疗法的局限性。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Werewolf Therapeutics</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>How to Invest in Biotech Stocks</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Werewolf Therapeutics</li>
<li>市值计算器：如何计算市值</li>
<li>在股价上涨 35% 后，分析师看好铜业巨头 Freeport 的进一步上涨</li>
<li>如何利用高贝塔股票最大化投资收益</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的主要催化剂</li>
<li>如何投资生物科技股票</li>
<li>Upwork 能否维持其复苏？看涨和看跌的理由</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SE9XTA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=HOWL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Werewolf Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Werewolf Therapeutics 吗？</h2>
</div><p>Before you consider Werewolf Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Werewolf Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Werewolf Therapeutics 并不在名单上。</p>
</div><p>While Werewolf Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Werewolf Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内幕交易：Werewolf Therapeutics（NASDAQ:HOWL）的一位董事出售了 14,548 股股票